$ALDX Phase 2 results on May 1st stock could soar.

Sentiment has been very positive in ALDEYRA THERAPEUTICS having already released positive results for other pipeline drugs. On may 1st phase 2 results for its new Dry Eye Syndrome drug will be presented and optimism is high on the rumor mill. The current price target by 7 analysts covering the name is $31 which is considerable higher than current levels.


Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.